Harrison Sicheng Lin

Harrison Sicheng Lin

Auto-generated profile, based on publicly available information

Harrison Sicheng Lin

The Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HLHarrison Sicheng Lin
Harrison Sicheng Lin
QDQiang Ding
Qiang Ding
ZLZsuzsanna Lichner
Zsuzsanna Lichner
SKSung Sun Kim
Sung Sun Kim
RSRola M Saleeb
Rola M Saleeb
GYGeorge Yousef
George Yousef
With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compared tumor growth rate, morphological, and transcriptomic differences between alternative and traditional treatment schedules. Our results show that the alternative treatment regime could delay/postpone cancer progression. Additionally, we identified distinct morphological changes in the tumor with alternative and traditional treatments, likely due to the significantly dysregulated signaling pathways between the protocols. Further investigation of the signaling pathways underlying these morphological changes may lead potential therapeutic targets to be used in a combined treatment with sunitinib, which offers promise in postponing/reversing the resistance of sunitinib.